Baraliakos, X., Braun, J., Laurent, D., Baeten, D., van der Heijde, D., Sieper, J., . . . Hueber, W. (2013). Long term IL-17A inhibition by secukinumab leads to reduced spinal inflammation and unchanged fatty lesions in patients with ankylosing spondylitis.
Style de citation Chicago (17e éd.)Baraliakos, X., et al. Long Term IL-17A Inhibition by Secukinumab Leads to Reduced Spinal Inflammation and Unchanged Fatty Lesions in Patients with Ankylosing Spondylitis. 2013.
Style de citation MLA (9e éd.)Baraliakos, X., et al. Long Term IL-17A Inhibition by Secukinumab Leads to Reduced Spinal Inflammation and Unchanged Fatty Lesions in Patients with Ankylosing Spondylitis. 2013.
Attention : ces citations peuvent ne pas être correctes à 100%.